

23RD ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and
Contract Manufacturing Organizations*



INSTITUTION PARTNERS



MEDIA PARTNERS



23RD ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and
Contract Manufacturing Organizations*

April 2026



BioPlan Associates, Inc.
One Research Court, Ste. 450
Rockville, MD 20850 USA
301.921.5979
www.bioplanassociates.com

Copyright ©2026 by BioPlan Associates, Inc.

All rights reserved. Unauthorized reproduction strictly prohibited.

23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

April 2026

BioPlan Associates, Inc.
One Research Court, Ste. 450
Rockville, MD 20850
1-301-921-5979
www.bioplanassociates.com

Copyright © 2026 by BioPlan Associates, Inc.

All rights reserved, including the right of reproduction in whole or in part in any form. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the publisher.

For information on special discounts or permissions contact
BioPlan Associates, Inc. at 301-921-5979, or info@bioplanassociates.com

Managing Editor:	Ioanna Deni
Design and Production:	Donnie E. Hubert
Contributing Editors:	Dr. Smita Khanna
Layout and Cover Design:	ES Design

ISBN 978-1-934106-53-2

ACKNOWLEDGMENTS

We wish to acknowledge the contributions of our authors and **Subject Matter Experts**. Without their added subject matter contributions, this project would not have been possible:

- Monika Birdi, Principal Product Manager for Advanced Therapies, SAP Americas
- Katrina Cordovado, MBDC, Business Development Manager, ENABLE Biotech
- Renaud Jacquemart, PhD, MBA, CEO, Omnium Global and Partner, BioPlan Associates
- Vadim Klyushnichenko, Ph.D., VP Bio/Pharmaceutical Development and Quality, Calibr-Skaggs Institute for Innovative Medicines (Scripps Research)
- Fran Lasowski, PhD, Chief Innovation Officer, Omnium Global
- Stefan Schmidt, PhD, CSO, Atlas Antibodies Group

We would also like to recognize our Institution Partners, and our Media Sponsors. Their efforts in assuring the cooperation and participation in the survey of their respective memberships helped guarantee the large group of survey participants to ensure data accuracy.

Our **Institution Partners**, all of whom contributed their time and effort to ensure the broad, international coverage of this project, include:

- AusBiotech (Malvern, Victoria, Australia)
- Bio-Process Systems Alliances/SOCMA (BPSA) (Washington, D.C., USA)
- D2L Pharma (Bangalore, India)
- Evaluating Biopharma (Rockville, MD, USA)
- North Carolina Biotechnology Center (Research Triangle Park, NC, USA)
- Pharma & Biopharma Outsourcing Association (PBOA) (Ringwood, NJ, USA)

To ensure global coverage for this project, we again invited major **Media Sponsors** to support our outreach to biopharmaceutical decision-makers. Our media sponsors, who helped ensure broad and representative coverage of industry participation, include:

- American Pharmaceutical Review/Pharmaceutical Outsourcing (South San Francisco, CA, USA)
- BioPharm International (Iselin, NJ, USA)
- BioProcess International (Westborough, MA, USA)
- BioProcess Online (Erie, PA, USA)
- Contract Pharma, (Ramsey, NJ, USA)
- CPhI (London, UK)
- Pharmaceutical Manufacturing (Schaumburg, IL, USA)
- Pharmaceutical Technology/Pharmaceutical Technology Europe (Iselin, NJ, USA)

The early participation of our authors and sponsors in evaluating the areas and trends to be surveyed this year ensured the project was designed to cover the most relevant issues in biopharmaceutical manufacturing today. As always, their continued support was critical to the success of the project.

Eric S. Langer, Publisher

ABOUT BIOPLAN ASSOCIATES, INC.

BioPlan Associates, Inc. is a biotechnology and life sciences market analysis, research, and publishing organization. We have managed biotechnology, biopharmaceutical, diagnostic, and life sciences research projects for companies of all sizes for over 30 years. Our extensive market analysis, research and management project experience covers biotechnology and biopharmaceutical manufacturing, vaccine and therapeutic development, contract research services, diagnostics, devices, biotechnology supply, physician office labs and hospital laboratory environments.

We prepare custom studies and provide public information our clients require to make informed strategic decisions, define objectives, and identify customer needs. With market information, our clients are better able to make informed, market-based decisions because they understand the trends and needs in high technology industries.

BioPlan Associates, Inc.
One Research Court, Ste. 450
Rockville, MD 20850 USA
www.bioplanassociates.com
+1 301-921-5979

EDITORS

Eric S. Langer, MS, President, BioPlan Associates, Inc.

Mr. Langer is President and Managing Partner at BioPlan Associates, Inc., a biotechnology, and life sciences consulting company that has been providing management and market strategy services, and technology analysis to biopharmaceutical and healthcare organizations since 1989. He has over 30 years' experience in biotechnology and life sciences management and market assessment. He is an experienced medical and biotechnology industry practitioner, strategist, researcher, and science writer. He has held senior management and marketing positions at biopharmaceutical supply companies. He teaches Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication at Johns Hopkins University, American University, and lectures extensively on pricing and channel management topics. Mr. Langer has a degree in Chemistry and a Masters in International Business. He has written and consulted extensively for companies involving large scale biopharmaceutical manufacturing, global biotechnology in China, Asia, and the Middle East; he has expertise in cell culture markets, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many other areas.

Ioanna Deni, Technical Director, Research

Ioanna Deni is Technical Director, Research at BioPlan Associates. She is an experienced quantitative market research analyst with a Ph.D. in biomedical sciences and extensive experience in biopharmaceutical life science research. Her research background includes quantitative and qualitative market research expertise as an AI and healthcare specialist at Intelligence Ventures.

Dr. Smita Khanna, Technical Director, Research

Smita Khanna, PhD, is Technical Director, Research at BioPlan Associates. With a PhD in Biotechnology, she has over 20 years' experience as a biopharmaceutical and healthcare market researcher/analyst, and extensive experience working in key industry segments. Her background includes the Council of Scientific & Industrial Research-Indian Institute of Toxicology Research (CSIR-IITR), India, and her expertise includes primary and secondary research, and market analysis of healthcare and biopharmaceutical segments. In addition, she contributes to international publications and journals, and research for in-depth reports.

Donnie E. Hubert, Senior Director, Research Projects

Donnie E. Hubert is Senior Director, Research Projects at BioPlan Associates. She has over 20 years' experience in marketing and healthcare research. She is editor and manager of several industry publications, reports, and databases, including the Report and Survey of Biopharmaceutical Manufacturing Capacity and Production and the Top1000Bio Facility Index and Database. She also oversees the Biotechnology Industry Council (BIC), a panel of subject matter experts in the biopharmaceutical industry providing in-depth knowledge to research projects. In addition, she provides secondary marketing research services as well as primary qualitative research.

ABOUT THE AUTHORS: (ALPHABETICAL)

Monika Birdi, Principal Product Manager for Advanced Therapies, SAP Americas

Monika Birdi is the global product strategy leader for Advanced Therapies at SAP Americas. She is focused on strengthening the digital backbone of biopharmaceutical manufacturing to support the safe and scalable delivery of advanced therapies. Her work centers on the design of GxP compliant digital architectures that enable end to end traceability, data integrity, and inspection readiness for patient specific treatments, including cell therapies.

Katrina Cordovado, MBDC, Business Development Manager, ENABLE Biotech

Katrina Cordovado is a biomedical commercialization specialist with a strong background in business development, market strategy, and client engagement for life science and biomanufacturing companies. At Enable Biotech, she leads outreach and proposal development efforts to support early-stage companies in cell therapy, gene-modified cell therapy, and exosome-based therapeutics. She plays a key role in ensuring smooth onboarding and long-term collaboration between clients and the CDMO's technical and commercial teams. Her experience also includes contributing to commercialization, market intelligence, and corporate development efforts at organizations such as Fina BioSolutions, a leading recombinant protein manufacturer, and Omnium Global, a strategic advisory firm serving biotech and CDMO clients. Katrina has supported projects involving regulatory and reimbursement strategy, QMS implementation, and investor communications across several ventures in the advanced therapies space.

Renaud Jacquemart, PhD, MBA, CEO, Omnium Global and Partner, BioPlan Associates

Renaud Jacquemart is a strategic leader and biopharmaceutical product development expert with 25 years of international experience. His expertise spans the full lifecycle of biologics—from early-stage development to commercialization—with a focus on cost-effective, scalable solutions. He provides strategic guidance on go-to-market planning, CMC program design and execution, and M&A, helping biopharma companies achieve growth, operational excellence, and competitive advantage. He previously held leadership roles at Sanofi Pasteur, Merck KGaA, Batavia Biosciences, and BioVectra, where he led global health programs and advanced next-generation manufacturing platforms for biologics and ATMPs. Renaud has directed engineering and technology transfer projects across five continents, including the design of large-scale vaccine facilities, modular and microfacility platforms, and decentralized manufacturing strategies. He has played a key role in bringing innovative bioprocess technologies to market and enabling successful partnerships and acquisitions by major industry players. In addition to leading Omnium Global, he holds executive and board positions with several emerging ventures. He has contributed to global health and access to-technology initiatives in over 30 countries, supporting the development and distribution of affordable, life-saving biologics in collaboration with international organizations, NGOs, and private-sector partners. His dual expertise in technical innovation and business strategy ensures that bioprocess solutions are not only robust and compliant but also aligned with real-world market needs.

Vadim Klyushnichenko, PhD, VP Bio/Pharmaceutical Development and Quality, Calibr-Skaggs Institute for Innovative Medicines (Scripps Research)

Vadim Klyushnichenko, PhD, is a bio/pharmaceutical development and operations specialist with over 25 years of leadership experience in advancing innovative therapies from concept to market. At the Calibr–Skaggs Institute for Innovative Medicines (Scripps Research), he serves as Vice President of Bio/Pharmaceutical Development and Quality, leading pharmaceutical development and manufacturing activities across a portfolio of programs supporting IND-enabling and clinical studies. He plays a key role in driving technology transfer and CMC strategy across advanced modalities, including conjugated proteins, vaccines, and cell and gene therapies. His extensive industrial background includes senior leadership roles at organizations such as Pfizer/Wyeth BioPharma, Sanofi, Baxter, and Paragon Bioservices, a leading biologics CDMO. Dr. Klyushnichenko holds a Ph.D. in Analytical Biochemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and has supported global programs involving complex drug/device combinations, scale-up, and clinical manufacturing milestones.

Fran Lasowski, PhD, Chief Innovation Officer, Omnium Global

Frances Lasowski, PhD, is Chief Innovation Officer at Omnium Global, where she supports biotechnology and life science companies in technology assessment, product development strategy, and commercialization. With more than 15 years of experience in biomaterials, drug delivery, and translational research, she has helped advance numerous healthcare innovations from academic research to commercial application. Dr. Lasowski is also Co-Founder and CEO of 20/20 OptimEyes Technologies and serves as an Adjunct Professor in the Faculty of Engineering at McMaster University.

Stefan R. Schmidt, PhD, CSO, Atlas Antibodies Group

Stefan R. Schmidt, PhD, serves as CSO, Atlas Antibodies Group. He was the former CEO at Evitria AG in Zürich, Switzerland for 3 years after spending five years as COO at BioAtrium AG, a Lonza and Sanofi JV. Previously he held the position as CSO and other senior executive roles at Rentschler Biopharma with overall responsibilities for development, production, and innovation. Before that, he was CSO at ERA Biotech in Barcelona, directing the company's R&D efforts. Prior to that, he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences as Associate Director. He started his leadership career in Munich more than 25 years ago where he built up protein biochemistry teams for Connex and GPC-Biotech. During his academic education he earned a PhD in Biochemistry and an MBA in Marketing.

23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production • April 2026

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

CONTENTS

METHODOLOGY.....	XXIX
-------------------------	-------------

CHAPTER 0: DEMOGRAPHICS	1
KEY TAKEAWAYS.....	1
INTRODUCTION	1
0-1 RESPONDENTS' AREA OF INVOLVEMENT.....	2
0-2 RESPONDENTS' QUALIFICATIONS.....	4
0-3 FACILITY LOCATIONS	6
0-4 AREAS OF BIOPHARMACEUTICAL MANUFACTURING OPERATIONS.....	9
0-5 PRODUCTION OPERATIONS, PHASE OF DEVELOPMENT.....	11
0-6 EMPLOYEES AT FACILITY	14
0-7 BATCHES RUN AT FACILITY PER YEAR.....	15
0-8 SINGLE-USE BIOREACTOR CAPACITY IN USE AT SITE.....	17
Analysis of Average Single-use Bioreactor Size	19
0-9 STAINLESS STEEL BIOREACTOR CAPACITY IN USE AT SITE	20
Analysis of Average Stainless Steel Bioreactor Size	22

CHAPTER 1: INTRODUCTION AND DISCUSSION	23
1-1 SECTOR AND MARKET OVERVIEW.....	23
The Industry Continues to Mature.....	24
M&A Activities	25
"Biopharmaceutical." - The Definition Used Here.....	25
Contract Manufacturing Trends.....	26
1-2 BIOPHARMACEUTICAL INDUSTRY STATUS AND MARKET TRENDS.....	27
U.S. Healthcare is Changing	28
Bioprocessing is Increasing Internationally	28
1-3 PHARMA INDUSTRY IS SHIFTING TO BIOPHARMACEUTICALS	30
Pharmaceutical Industry Dependence on Biopharmaceuticals.....	30

1-4	GLOBAL BIOPHARMACEUTICAL MARKET TRENDS	31
	Growth in Biopharmaceutical Product Sales is Increasing the Demand for Bioprocessing	32
	Overall Health of the Biopharmaceutical Sector	37
	U.S. Industry Leadership Continues	38
	Biopharmaceuticals in the Rest-of-the-World.....	39
1-5	BIOPHARMACEUTICAL MARKETS BY PRODUCT CLASS	41
	Monoclonal Antibodies (mAbs) are the Leading Product Class	41
	Monoclonals are a Costly Treatment	42
1-6	ANIMAL DERIVED PRODUCTS AND BIOPHARMACEUTICALS.....	43
	Animal Derived Products and Biopharmaceuticals	43
	Plant-based Biopharmaceutical Manufacturing	44
1-7	FUTURE TRENDS IN THE BIOPHARMACEUTICAL INDUSTRY	45
	Future Trends in Biopharma	45
	Conclusion	49
CHAPTER 2: FUTURE OF BIOPROCESSING: EXPERTS' PERSPECTIVE		51
2-1	2025 FDA Biopharmaceutical Approvals: Promising Year for Novel Biologics Driven by Innovation and Targeted Therapies	52
2-2	Recent Transactions Affecting the CDMO Landscape in 2025	59
2-3	Artificial Intelligence in Biopharmaceutical Development, Manufacturing, and Quality	63
2-4	Vein-to-Vein Manufacturing: Why Cell Therapy Requires a Patient-Centric Compliance Model.....	66
2-5	Can CDMOs Meet the Demand for Capacity in Peptide and Oligonucleotide Therapeutics Manufacturing?.....	69
CHAPTER 3: TRENDS AND EMERGING TECHNOLOGIES		75
	KEY TAKEAWAYS	75
3-1	INDUSTRY TRENDS IN 2025	76
	Background and Definitions	76
3-2	BIOPROCESSING IMPROVEMENTS NEEDED IN 2026	77
	Bioprocessing Improvements Most Needed	77
	Novel Bioprocessing Systems/Innovations	79
	Novel Bioprocessing Systems/Innovations, Biomanufacturers vs. CMOs	85
3-3	OPERATIONAL CHANGES IN PRE- AND POST-COVID	87
	Operational Changes Due to Recent Global Economics	87
	Operational Changes (2010 – 2012, 2022-2026)	89
	Operational Changes: Biomanufacturers vs. CMOs	92
	Operational Changes: U.S. vs. Western Europe.....	94
3-4	BUDGET ISSUES IN 2026	96
	Biomanufacturers' Budget Shifts in 2026	96
	Budget Change Comparisons (2009-2026)	99

3-5	TOP BIOPROCESSING BUDGET EXPENDITURES	103
	New Expenditures Focus Areas in 2026	103
	Top New Bioprocessing Budget Expenditures (2020-2026)	106
3-6	NEW BIOPROCESSING PRODUCTS DEVELOPMENT OPPORTUNITIES (2026)	108
	Upstream New Product Areas of Interest, 2026.....	108
	Trends: Upstream New Product Areas of Interest (2010-2026).....	111
	Downstream New Product Areas of Interest, 2026	113
	Analysis Of Key Finding: Demand for New Product Development in Upstream Bioprocessing	113
	Trends: Downstream New Product Areas of Interest (2010-2026)	117
	Other General New Product Areas of Interest, 2026	119
	Trends: Other General New Product Areas of Interest (2010-2026).....	121
	New Product Development Areas: Biomanufacturers vs. CMOs	123
	New Product Development Areas: U.S. vs. Western Europe and ROW.....	125
3-7	FACTORS IN BIOMANUFACTURING CREATING IMPROVEMENTS	127
	Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements, 2026	128
	Factors Improving Biomanufacturing Performance (2010-2015, 2025-2026).....	130
	Factors Improving Biomanufacturing Performance, Biotherapeutic Developers vs. CMOs	132
	Factors Improving Biomanufacturing Performance, U.S. vs. Western Europe vs. ROW.....	134
3-8	COST-CUTTING ACTIONS & DEVELOPMENT TIMELINES.....	136
	Cost-Cutting Changes: Actions Undertaken During 2011-2016, 2019-2024.....	136
	Cost-Cutting Changes: Specific to Outsourcing.....	138
	Factors Impacting Reduction in Cost of Goods (2020-2024).....	140
3-9	AVERAGE COST PER GRAM RECOMBINANT PROTEIN	141
	Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2026	141
	Distribution, Average Cost per Gram for PRIMARY Recombinant Protein (2017-2026)	142
	Analysis of Key Finding: Some Good from the Pandemic. Cost per Gram in Biomanufacturing Proteins dropped 10% annually during COVID.....	143
3-10	ASSAY DEVELOPMENT.....	144
	Biomanufacturing Assay Areas Required; Biomanufacturers vs. CMOs.....	146
	Biomanufacturing Assay Areas Required, U.S. vs Western Europe	148
3-11	SELECTING AND PURCHASING COMMERCIAL-SCALE BIOREACTORS	150
	Largest Commercial-Scale Bioreactor Expected in Next Two Years (2022)	150
	Top Options for Bioreactor Platforms at Commercial Scale	151
	Top Options for Bioreactor Platforms at Commercial Scale (2021-2024)	153
	Largest Single-Use Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2025)	155
	Largest Stainless Steel Bioreactor Capacity Purchase in ‘Next Two Years’, 2022, 2025-2026.....	156

3-12 DISCUSSION: INDUSTRY TRENDS AND ISSUES.....	158
Industry Growth and Adaptation.....	158
Cost Cutting Trends	159
Discussion of Cost per Gram	159
Discussion of Maturity of Single Use	159
CHAPTER 4: CAPACITY UTILIZATION	161
KEY TAKEAWAYS	161
4-1 CAPACITY UTILIZATION TRENDS	162
Capacity Utilization Definitions.....	162
Relevance of Capacity Utilization	162
Capacity Utilization in Other Industries, 2026: US Federal Reserve Board Comparisons	163
Capacity Utilization in Biomanufacturing by System, 2026.....	164
Capacity Utilization Changes (2006-2026)	165
Average Growth Rate in Capacity Utilization (2006-2026).....	167
4-2 CAPACITY UTILIZATION: BIOMANUFACTURERS VS. CMOS	167
Capacity Utilization By System, Biomanufacturers vs. CMOs, 2026	168
4-3 CAPACITY UTILIZATION: U.S. VS. WESTERN EUROPEAN MANUFACTURERS	171
Capacity Utilization, By System, U.S. vs. Western Europe.....	171
Historical 14-year US vs. EU Trends in Capacity Utilization	172
4-4 RESPONDENTS' CURRENT TOTAL PRODUCTION CAPACITY	174
Mammalian Cell Culture Capacity.....	174
Microbial Fermentation Capacity	178
Cell Therapy Capacity.....	182
Gene Therapy Capacity	186
4-5 GLOBAL BIOREACTOR CAPACITY.....	190
The Largest Capacity Facilities	191
Biopharmaceutical Capacity Expansions Continue	193
Biopharmaceutical Developers/Manufacturers as CMOs	194
Major CMOs in Terms of Facilities and Capacity	194
4-6 RANGE OF TITERS WITH MAB PRODUCTION.....	195
Distribution of mAb Titer Ranges	196
Annual mAb Titer Changes (2008-2026)	198
4-7 DISCUSSION: CAPACITY AND INDUSTRY TRENDS.....	199
The Risks of Biomanufacturers Seeking to Become a CMO	199
Future Capacity Trends.....	200
CHAPTER 5: CURRENT AND FUTURE CAPACITY CONSTRAINTS AND QUALITY FACTORS	201
KEY TAKEAWAYS	201
5-1 CURRENT CAPACITY CONSTRAINTS	202
Background & Definitions.....	202

Current Capacity Constraints	202
Respondents' Perception of Capacity Constraints (2004-2026)	205
Differences in Capacity Constraints: Biomanufacturers vs. CMOs	208
Capacity Constraints: U.S. vs. Western European Biomanufacturers & CMOs.....	209
5-2 EXPECTED CAPACITY CONSTRAINTS.....	211
Respondents' Expectations of Capacity Constraints in Five Years (2031)	211
Expected Capacity Constraints Five-year Projections (2004-2026)	212
Expected Capacity Constraints in Five Years: Biomanufacturers vs. CMOs (2031)	215
Expected Capacity Constraints in Five Years: U.S. vs. Western Europe (2031)	216
5-3 FACTORS IMPACTING FUTURE PRODUCTION CAPACITY	217
Factors Creating Future Capacity Constraints in Five Years (2031)	217
Factors Creating Future Capacity Constraints (2008-2026)	219
Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs	223
CMO Capacity Bottleneck Projections, in Retrospect	225
Factors Creating Capacity Constraints: U.S. vs. Western Europe Respondents.....	226
5-4 KEY AREAS TO ADDRESS TO AVOID FUTURE CAPACITY CONSTRAINT	228
Areas to Avoid Capacity Constraints in 2026	228
Areas to Avoid Capacity Constraints: Changing Perspectives (2006-2026)	230
Key areas to Address to Avoid Capacity Constraints; Biomanufacturers vs. CMOs	233
Key Areas to Address to Avoid Capacity Constraints: U.S. vs. Western Europe	235
5-5 BATCH FAILURES IN BIOPHARMACEUTICAL MANUFACTURING	237
Background and Definitions	237
Average Time Between Batch Failures (2009-2026)	238
Batch Failure Frequency Distribution (2009-2026)	239
Primary Cause of Batch Failures, Percentages of Failures	241
Primary Cause of Batch Failures, Percentages of Failures for Commercial Manufacturing (2009-2026).....	244
Primary Cause of Batch Failures, Percentages of Failures for Clinical Scale Manufacture (2009-2026)	246
Improving Failure Rates	248
5-6 QUALITY PROBLEMS IN BIOMANUFACTURING ATTRIBUTED TO VENDORS	249
Global Quality Supply Management (2011-2013, 2022-2023) – 2023 Data	249
Global Quality Supply Management Biomanufacturers vs. CMOs (2023)	252
U.S. vs. W. Europe Global Quality Supply Management (2023).....	253
Addressing Supply Chain Security Post Pandemic	254
5-7 DISCUSSION: INDUSTRY TRENDS.....	255
Mitigation Strategies for Financial Constraints in Biomanufacturing	256
Automation and Artificial Intelligence to Address Capacity Constraints	257
CHAPTER 6: PLANNED FUTURE CAPACITY EXPANSIONS	259
KEY TAKEAWAYS	259
6-1 PLANNED FUTURE CAPACITY EXPANSIONS.....	260
Background and Definitions	260
Industry Average Planned Production Increases, Five Years Estimates (2031)	261

	Planned Future Capacity Expansions: Five Year Estimates (2009-2031)	262
	Planned Future Capacity Expansions of >100%, by Systems	264
6-2	PLANNED FUTURE CAPACITY EXPANSIONS FOR BIOMANUFACTURERS VS CMOs, BY SYSTEM.....	266
	Planned Future Capacity Expansions for Biomanufacturers vs. CMOs, Five Year Estimates (2031)	266
6-3	PLANNED FUTURE CAPACITY EXPANSIONS FOR U.S. VS. WESTERN EUROPE, BY SYSTEM	267
	Planned Future Capacity Expansions for U.S. vs. W. Europe Manufacturers, Five Year Estimates (2031)	267
6-4	PLANNED FUTURE CAPACITY EXPANSIONS.....	270
	Biomanufacturing Capacity Under Active Construction in 2026.....	271
6-5	DISCUSSION: FUTURE OF CAPACITY EXPANSION TRENDS	272
	Drivers of Platform-specific Capacity Expansion	272

CHAPTER 7: OUTSOURCING TRENDS IN BIOPHARMACEUTICAL MANUFACTURING275

	KEY TAKEAWAYS.....	275
7-1	BACKGROUND AND DEFINITIONS	276
	Why Outsource?	277
	Strategic Manufacturing Planning	277
	Future Projections.....	278
7-2	CURRENT OUTSOURCING BY PRODUCTION SYSTEM.....	278
	Facilities Currently Outsourcing Production by System (2026).....	279
	Facilities Currently Outsourcing No Production (All Production “In-house”) (2006-2026)	281
	Historical Trends in Outsourcing Production	283
7-3	FUTURE OUTSOURCING.....	284
	Biotherapeutic Developers’ Outsourcing, 5-Year Projections, by System (2031)	284
	Five Year Projections for Biomanufacturers Outsourcing Some Production	287
7-4	OUTSOURCED ACTIVITIES IN BIOPHARMACEUTICAL MANUFACTURING	289
	Biomanufacturers Outsourcing Some Activity Today, 2026.....	290
	Comparison of Biomanufacturers’ Outsourcing, (2010-2026).....	292
	Increased Outsourced Activities, 24-Month Projections.....	295
	Outsourcing Activities Projected at ‘Significantly Higher Levels’ (2010-2026)	298
	Percentage of Activities Outsourced Today, 2026	301
	Comparison of Outsourcing Activities (2010-2026).....	303
	Change in Average Spending on Outsourcing Activities	306
	Change in Average Spending on Outsourcing by Facilities (2013-2026).....	308
7-5	CRITICAL OUTSOURCING ISSUES	309
	Key Attributes CMOs Must Deliver their Clients.....	309
	Selecting a CMO, 2006-2018, 2025-2026	311
	Proximity of CMOs to the Client	313

7-6	CMOS' PROBLEMS WITH THEIR CLIENTS.....	313
	CMOs Problems with Their Clients	313
7-7	COUNTRY SELECTIONS FOR INTERNATIONAL OUTSOURCING (OFFSHORING) OF BIOMANUFACTURING.....	314
	U.S. BioSecure Act Impact on Offshoring (2025 data).....	314
	USA as Likely for INTERNATIONAL (non-US respondents) Outsourcing Over Next Five Years	317
	Possible" Selections for International Outsourcing (Offshoring) of Biomanufacturing, Over Five Years (2016-2026).....	320
	U.S.-based Companies "Possible" Outsourcing Destinations.....	324
	U.S.-based Companies "Likely" Outsourcing Destinations	327
	W. European – based Companies "Possible" Outsourcing Destinations	329
	W. European – based Companies "Likely" Outsourcing Destinations	333
7-8	OFFSHORING TRENDS TO LOWER-COST REGIONS	335
	5-Year Projection for Biomannufacturing International Outsourcing /Offshoring to Lower-Cost Regions	335
	Five Year Projection for Biomannufacturing International Outsourcing/ Offshoring to Lower-Cost Regions (2011-2026)	338
	Five Year Projection for Average Percentages of Biomannufacturing International Outsourcing/Offshoring to Lower-Cost Regions (2011-2026)	340
	Outsourcing to New Regions (2020 data).....	342
7-9	DISCUSSION: OUTSOURCING AND OFFSHORING.....	342
	Trends and Drivers of Outsourcing	342
	Strategic Shifts in Outsourcing.....	343
	Future Projections.....	343

CHAPTER 8: DISPOSABLES AND SINGLE-USE SYSTEMS IN BIOPHARMACEUTICAL MANUFACTURING345

	KEY TAKEAWAYS.....	345
8-1	USE OF DISPOSABLES AND SINGLE-USE SYSTEMS.....	346
	Background and Definitions	346
	Disposables Applications in Biopharmaceutical Manufacturing	347
	Trends in Disposable Applications (2006-2026).....	349
	Average Annual Growth Rate for Disposables: 20 Years of Market Penetration and Usage	352
	20-Year Average Growth In Disposable Applications, Percentage-Point Gains.....	355
	Disposable Use by Stage of Production/Application.....	357
	Use of Disposables: Biomannufacturers vs. CMOs	359
8-2	LEACHABLES AND EXTRACTABLES.....	361
	Issues Related to Leachables and Extractables (2018 data).....	361
8-3	REASONS FOR INCREASING USE OF DISPOSABLES & SINGLE-USE SYSTEMS.....	362
	Single Most Critical Reason for Increasing the Use of Disposables	362
8-4	FACTORS THAT MAY RESTRICT USE OF DISPOSABLES.....	366
	Factors that May Restrict Use of Disposables, 2026	367

Most Important Factors That May Restrict Use of Disposables (2006-2015, 2025-2026)	369
Cell-Culture Problems due to Single-Use Devices (2021 vs. 2022)	371
Recycling of Disposables (2020)	371
8-5 SINGLE-USE ADOPTION ISSUES	372
Evolution of SUS Adoption	372
Single-use Failures by Timeframe and SUS Type	373
Average Weeks Before Failures of Single-use Devices (2023-2026)	375
8-6 NEED FOR SINGLE-USE SENSORS, AND BIOREACTOR ATTRIBUTES	377
Single-Use Sensor Technologies (2012-2017, 2019, 2026)	377
8-7 SATISFACTION WITH SINGLE-USE DEVICE VENDORS (2008-2026)	379
Single-Use Product Vendor Satisfaction Factors (2008-2026)	379
Single-Use Attribute Importance Analysis	382
Single-Use Suppliers' Issues (2013-2026)	384
8-8 SINGLE-USE OPERATIONS AND TRENDS	387
Percentage of Unit Operations that are Single-Use (2014-2026)	387
Percentage of Single-Use Device Usage in Biomanufacturing	389
8-9 DISCUSSION: SINGLE-USE BIOPROCESSING	391
Single-use Advantages	391
Growth in the Use of Single-use Systems	391
Downstream Single-use Systems Usage	392
CMOs' Use of Single-use Equipment	393
Modular: The Next Trend after Single-Use?	393
Single-use Equipment Sourcing, Quality Issues, and L&E Testing	394

CHAPTER 9: DOWNSTREAM PURIFICATION397

KEY TAKEAWAYS	397
9-1 IMPACT OF DOWNSTREAM PROCESSING ON CAPACITY	398
Background and Definitions	398
Impact of Downstream Processing on Overall Capacity	398
Impact of Downstream Processing on Capacity, Biomanufacturers vs. CMOs	401
Impact of Downstream Processing on Capacity, U.S. vs. Western European Biomanufacturers	402
9-2 SPECIFIC PURIFICATION STEP CONSTRAINTS	404
Background on Purification Processes in DSP	404
Changes in Impact on Capacity of Purification Steps (2008-2026)	406
Specific Purification Step Constraints, U.S. vs. Western European Biomanufacturers	408
9-3 DOWNSTREAM PURIFICATION ISSUES	410
Protein A and Alternatives (2022 data)	410
Changes in Perception of Protein A and Alternatives (2009-2017, 2020-2022)	411
9-4 MAB PURIFICATION CAPACITY ESTIMATES	412
Upstream Production Titer vs. Max Capacity	412
Over-building of DSP Capacity to Handle Available Bioreactor Capacity	412

9-5	NEW DOWNSTREAM PROCESSING TECHNOLOGIES	417
	New Downstream Processing Solutions (2010-2026)	419
	New Downstream Processing Technologies; Biomanufacturers vs. CMOs	422
	New Downstream Processing Technologies: U.S. vs. Western Europe	424
9-6	IMPROVEMENTS TO DOWNSTREAM OPERATIONS.....	426
	Drivers of Downstream Processing Bottlenecks	426
	Improving Downstream Operations (2011-2019, 2025-2026).....	427
9-7	FILL FINISH TRENDS	429
	Background and Definitions	429
	Fill-Finish Trends (2025)	430
	Recent Industry Trends	432
	New Technology Implementation in Fill-Finish	432
	Outsourcing Fill/Finish	434
9-8	DSP Yield in Primary Process.....	434
9-9	DISCUSSION: INDUSTRY TRENDS.....	437
	Downstream Processing Solutions	438
	Artificial Intelligence	439
	Continuous Downstream Bioprocessing	439
	Single-use systems.....	439
	Membrane-based Filtration	440

CHAPTER 10: HIRING, EMPLOYMENT GROWTH, AND TRAINING IN BIOPHARMACEUTICAL MANUFACTURING445

	KEY TAKEAWAYS.....	445
	Background and Definitions.....	445
10-1	HIRING TRENDS.....	446
	New Hires in Biopharmaceutical Manufacturing, 2026	447
	Trends in New Hires, by Area (2008-2026).....	447
10-2	FIVE YEAR TRENDS IN HIRING (2031).....	450
	New Hires in Biopharmaceutical Manufacturing in Five Years (2031)	450
10-3	HIRING CHALLENGES TODAY.....	451
	Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, 2026	451
	Hiring Difficulties (2010-2026).....	453
	U.S. and Western Europe Hiring Difficulties	457
10-4	TRAINING IN BIOPHARMACEUTICAL MANUFACTURING.....	459
10-5	DISCUSSION: STRATEGIES FOR SUCCESSFUL EMPLOYMENT GROWTH	461
	Root Causes of the Persistent Talent Gap	461
	Rapid Technology Evolution.....	461
	Multidisciplinary Skillset	461
	Insufficient Hands-On Training.....	462
	Supply–Demand Mismatch	462
	Retention Challenges.....	462
	Strategic Training	463
	Attractive Career Paths.....	463

CHAPTER 11: NEW METHODS: CONTINUOUS AND PROCESS INTENSIFICATION, CELL AND GENE THERAPIES	465
KEY TAKEAWAYS	465
INTRODUCTION TO INNOVATIVE BIOPROCESSING	466
Background and Definitions	466
Benefits of Cell and Gene Therapies	467
Benefits of Continuous Bioprocessing and Perfusion	467
11-1 FUTURE ADOPTION OF CONTINUOUS BIOPROCESSING AND PROCESS INTENSIFICATION	468
Future of Continuous Bioprocessing in 2026	469
Future of Continuous Bioprocessing (2018-2025)	471
11-2 PERFUSION OPERATIONS AND CONTINUOUS BIOPROCESSING OPERATIONAL ISSUES	474
Perfusion vs. Batch Fed Bioprocessing – Areas of Much Bigger Concern	474
Perfusion Operation Issues (2010-2014, 2016, 2020, 2023-2025)	477
Evaluating or Considering CBP technologies (Upstream) Over the Next 12 Months (2016-2025)	479
Evaluating or Considering CBP technologies (Downstream) Over the Next 12 Months (2016-2025)	481
Continuous Bioprocessing and Perfusion Trends	483
11-3 AUTOMATION IMPLEMENTATION	483
Demand for Automation	483
Comparison of Implementation Plans (2009-2013, 2022-2026)	486
The Role of Automation in Supporting Continuous Bioprocessing	488
Factor Inhibiting Greater Automation (2026)	489
11-4 ARTIFICIAL INTELLIGENCE (AI) ACTIVITIES	490
Artificial Intelligence in Biomanufacturing	490
Activities Considered Using Artificial Intelligence (AI) in the Next 2 Years (2028) ...	490
Challenges in Implementation of Artificial Intelligence (2026)	493
Activities Using Artificial Intelligence (AI) Today vs in the Next 2 Years (2028)	495
11-5 CELL AND GENE THERAPY PLATFORMS	497
Cell and Gene Therapy Manufacturing: A Catalyst for Innovation	497
Cell and Gene Therapy Manufacturing Trends	497
Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025)	498
Gene Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025)	501
Advanced Therapy (Cell or Gene Therapy) GMP and Commercial Manufacturing (2020-2025)	504
Cell Therapy Capacity Plans for In-House Bioprocessing Facilities: Five Year Estimates (2023-2025)	507
Cell Therapies Commercial Manufacturing Scales (2021)	509
Gene Therapy Vectors and Products Commercial Manufacturing Scales (2021)	509
11-6 DISCUSSION: FUTURE OF BIOMANUFACTURING	509
Looking Ahead: Industry Considerations and Strategic Imperatives	509

CHAPTER 12: SUPPLIERS TO BIOPHARMACEUTICAL MANUFACTURING AND LIFE SCIENCES	517
KEY TAKEAWAYS	517
12-1 DEMOGRAPHICS	518
Background and Definitions	518
Areas of Involvement	518
Location of Vendor Sales	521
Vendor / Supplier Respondents' Primary Job	524
12-2 GROWTH RATE OF SALES BY SUPPLIERS	525
Average Annual Vendor Sales Growth Rate	525
Distribution of Growth Rates	526
Average Industry Growth Rate, By Segment	527
Average Industry Growth Rate, By Segment (2007-2026)	528
Supplier Annual Sales, Distribution	530
12-3 BUDGET ISSUES AND PROBLEMS FACED BY INDUSTRY SUPPLIERS	532
Budget planning requires long-term projections for sales, segment growth and other trends	532
Budget Challenges in 2026	532
Vendor Average Pricing Changes	536
Vendor Projected 2026 Pricing Changes	537
12-4 PROBLEMS CLIENTS HAVE WITH THEIR VENDORS	539
Quality of Business Relationships with Suppliers	539
Quality of Business Relationships with Clients	542
Supplier Values:	542
Facility / Customer Values:	542
CMOs Problems with Their Clients (2018 data)	544
Quality Problems Traced to Vendors (2018 data)	544
12-5 IMPACTS OF COVID-19 ON SUPPLIERS' ACTIVITIES	545
Impact of COVID-19 Pandemic on Vendors, Percent Indicating an INCREASE in COVID-Related Factors (2021-2023)	545
Post COVID Impact on Suppliers: Permanent Changes on Business Operations ..	547
Biopharma Vendor Business Trends	548
Biopharma Vendor Business Trends (2010-2026)	551
12-6 VENDORS' PRODUCTS AND SERVICES	554
New Technology Areas in Development by Vendors	554
Suppliers' R&D Spending/Budgets for New Products/Services	559
12-7 SALES STAFF TRAINING	562
Areas where Training May Help Sales Staff Perform, Trends (2010-2026)	563
Client Demands of Vendors, Service and Support (2012-2026)	565
12-8 BIOPHARMA VENDORS' FINANCIAL OUTLOOK FOR 2026	567
12-9 CMO PRICING CHANGES FOR BIOPHARMACEUTICAL SERVICES	569
12-10 DISCUSSION: BIOPHARMA SUPPLIERS	572
Vendor and Industry Growth	572
Biopharma Suppliers in Emerging Regions	573

FIGURES

Fig 0.1:	Area of Primary Involvement in Biopharmaceutical Manufacturing (2010-2026).....	3
Fig 0.2:	Respondents' Job Responsibilities (2011-2026)	5
Fig 0.3:	Facility Location, 2026	7
Fig 0.4:	Facility Location, by Region, 2026	8
Fig 0.5:	Biopharmaceutical Manufacturing Systems, Trends (2007-2026)	10
Fig 0.6:	Phase of Development of Surveyed Respondents (2006-2026).....	12
Fig 0.7:	Phase of Development of Surveyed Respondents, U.S. vs. Western Europe (2026).....	13
Fig 0.8:	Distribution of Employees at Facility and Organization, 2026.....	14
Fig 0.9:	Distribution of Total Batches Run at Facility in Past 12 Months, by Scale of Production (2026).....	16
Fig 0.10:	Distribution of Largest SINGLE-USE Bioreactor Capacity (2017-2026)	18
Fig 0.11:	Average SINGLE-USE Bioreactor Volume (Liters) (2017-2026).....	19
Fig 0.12:	Distribution of Largest STAINLESS Bioreactor Capacity (2017-2026).....	21
Fig 0.13:	Average 'Largest' Stainless Steel Capacity (L) (2017-2026)	22
Fig 1.1:	Top 50 Biopharmaceutical Products, Percentage of Total Market Revenue	36
Fig 2.1:	Numbers of Recombinant and Non-Recombinant Biopharmaceuticals Approved by FDA Since 1982 (1982-2025)	52
Fig 2.2:	Number of Facilities, both Recombinant and Synthetic (SPPS), Peptide Therapeutics, All Scales, 2026, Percent	70
Fig 2.3:	Global Capacity for Synthetic (SPPS), Commercial-scale Peptide Therapeutics, 2026, Percent.....	70
Fig 2.4:	Factors Creating Future Capacity Constraints, Biomanufacturers vs. CMOs, 2026, Percent.....	71
Fig 3.1:	SINGLE Most Important Biomanufacturing Trend or Operational Area (2014-2026)	80
Fig 3.2:	Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (2018-2026)	82
Fig 3.3:	Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (Biomanufacturers vs. CMOs), 2026	86
Fig 3.4:	Operational Changes Due to Recent Global Economics, 2026	88
Fig 3.5:	Operational Changes Due to Recent Global Economics (2010 - 2012, 2022-2026)	90
Fig 3.6:	Operational Changes Due to Recent Global Economics; Biomanufacturers vs. CMOs, 2026	93
Fig 3.7:	Operational Changes Due to Recent Global Economics; U.S. vs. Western Europe, 2026.....	95
Fig 3.8:	Biomanufacturers' Budget Shifts, 2026.....	97
Fig 3.9:	Approximate Average Change in Biomanufacturers' Budgets, 2026	98
Fig 3.10:	Average Biomanufacturers' Budget Changes (2009-2026)	102
Fig 3.11:	New Expenditures Focus Areas, 2026.....	104
Fig 3.12:	New Expenditures Focus Areas (2020-2026)	107
Fig 3.13:	New Product Development-Upstream Focus Areas, 2026	110

Fig 3.14:	Upstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts (2010-2026)	112
Fig 3.15:	Downstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts, 2026.....	115
Fig 3.16:	New Product Development – Downstream Focus Areas (2010-2026)	118
Fig 3.17:	New Product Development – General Focus Areas, Biomanufacturers & CMOs, 2026	120
Fig 3.18:	New Product Development – General Focus Areas (2010-2026).....	122
Fig 3.19:	Top 10 New Product Development Areas of Interest: Biomanufacturers vs. CMOs, 2026	124
Fig 3.20:	Top 10 New Product Development Areas of Interest: U.S. vs. Western Europe vs. ROW, 2026	126
Fig 3.21:	Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements, 2026	129
Fig 3.22:	Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements (2010-2015, 2025-2026).....	131
Fig 3.23:	Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements: Biomanufacturers vs. CMOs, 2026	133
Fig 3.24:	Factors in Biomanufacturing Performance Creating “Significant” or “Some” Improvements: US vs. Western Europe vs. ROW, 2026.....	135
Fig 3.25:	Cost-Cutting Changes: Actions Undertaken During “Past 12 Months” Comparing (2011-2016, 2019-2024).....	137
Fig 3.26:	Cost-Cutting Changes, Outsourced Jobs, by Segment, (2011-2016, 2019-2024)...	139
Fig 3.27:	Factors That Will Have the Greatest Impact on REDUCING YOUR COST OF GOODS for Biotherapeutic Products (2020-2024)	140
Fig 3.28:	Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2026	142
Fig 3.29:	Distribution, Average Cost per Gram for PRIMARY Recombinant Protein (2017-2026)	143
Fig 3.30:	Biomanufacturing Assay “Areas” Urgently Requiring New, Improved Testing Methods (2011-2015, 2018-2019, 2024, 2026).....	145
Fig 3.31:	Biomanufacturing Assay ‘Areas’ Urgently Requiring New, Improved Testing Methods; Biomanufacturers vs. CMOs, 2026	147
Fig 3.32:	Biomanufacturing Assay ‘Areas’ Urgently Requiring New, Improved Testing Methods; US vs. Western Europe, 2026.....	149
Fig 3.33:	Largest Commercial-Scale Bioreactor Expected in the Next Two Years (2028)	151
Fig 3.34:	Top Options for Bioreactor Platforms at Commercial Scale, 2024	152
Fig 3.35:	Top Options for Bioreactor Platforms at Commercial Scale (2021-2024)	154
Fig 3.36:	Distribution of Largest Single-Use Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2026).....	156
Fig 3.37:	Distribution of Largest Stainless Steel Bioreactor Capacity to Purchase in Next Two Years (2022, 2025-2026).....	157
Fig 4.1:	Capacity Utilization, By System, 2026	165
Fig 4.2:	Capacity Utilization, By System (2006-2026).....	166
Fig 4.3:	Change in Capacity Utilization, CAGR (2006-2026)	167
Fig 4.4:	Capacity Utilization, By System, Biomanufacturers vs. CMOs, 2026	169
Fig 4.5:	Availability of CMO/CDMO Capacity (2024-2026)	170
Fig 4.6:	Capacity Utilization, By System, U.S. vs. Western Europe, 2026.....	172

Fig 4.7:	Western European vs. US Biomanufacturers' Average Capacity Utilization (2012-2026)	173
Fig 4.8:	Current Production Capacity Distribution, Mammalian Cell Culture, 2026	175
Fig 4.9:	Production Capacity Distribution, Mammalian Cell Culture (2010-2026).....	177
Fig 4.10:	Current Production Capacity Distribution, Microbial Fermentation, 2026	179
Fig 4.11:	Current Production Capacity Distribution, Microbial Fermentation (2010-2026).....	181
Fig 4.12:	Current Production Capacity Distribution, Cell Therapy, 2026.....	183
Fig 4.13:	Production Capacity Distribution, Cell Therapy (2020-2026).....	18
Fig 4.14:	Current Production Capacity Distribution, Gene Therapy, 2026	187
Fig 4.15:	Production Capacity Distribution, Gene Therapy (2020-2026)	189
Fig 4.16:	Bioprocessing Concentration, Capacity Data, 2026	191
Fig 4.17:	Range of Titers for mAbs Obtained at Various Production Scales, Distribution, 2026	197
Fig 4.18:	Average mAb Titer Trend (2008-2026).....	199
Fig 5.1:	Capacity Constraints, by Stage of Production, 2026	204
Fig 5.2:	Capacity Constraints 'Today' (2004-2026)	206
Fig 5.3:	Capacity Constraints Trends (2004-2026)	207
Fig 5.4:	Capacity Constraints, Biomanufacturers vs. CMOs, 2026	208
Fig 5.5:	Capacity Constraints, U.S. vs. Western Europe, 2026	210
Fig 5.6:	Expectations of Capacity Constraints by Stage of Production: Five-year Projections (by 2031)	212
Fig 5.7:	Expectations of Capacity Constraints: Five-year Projections (2004-2026).....	213
Fig 5.8:	Expectations of Capacity Constraints: Five-year Projections (Trend Line) (2004-2026)	214
Fig 5.9:	Five-year Projections for Capacity Constraints: Biomanufacturers vs. CMOs (2031).....	215
Fig 5.10:	Five-year Projections for Capacity Constraints: U.S. vs. Western Europe (2031)...	216
Fig 5.11:	Factors Creating Future Capacity Constraints in Five Years (2031).....	218
Fig 5.12A:	Factors Creating Future Capacity Constraints in Five Years (2008-2026).....	221
Fig 5.12B:	Factors Creating Future Capacity Constraints in Five Years (2008-2026).....	222
Fig 5.13:	Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs, 2026	224
Fig 5.14:	Factors Creating Future Capacity Constraints, U.S. vs. Western Europe Biomanufacturers, 2026	227
Fig 5.15:	Key Areas to Address to Avoid Capacity Constraints, 2026.....	229
Fig 5.16A:	Key Areas to Address to Avoid Capacity Constraints (2006-2026)	231
Fig 5.16B:	Key areas to Address to Avoid Capacity Constraints (2006-2026)	232
Fig 5.17:	Key Areas to Address to Avoid Capacity Constraints; Biomanufacturers vs. CMOs, 2026	234
Fig 5.18:	Key Areas to Address to Avoid Capacity Constraints; U.S. vs. Western Europe, 2026.....	236
Fig 5.19:	Average Time (weeks) Between Batch Failures (2009-2026).....	238
Fig 5.20:	Batch Failure Frequency Distribution (2009-2026)	240
Fig 5.21:	Average Rates of Failure, by Primary Cause, and Phase of Manufacture, 2026.....	242
Fig 5.22:	Average Rates of Failure, by Primary Cause, and Phase of Manufacturing (Commercial Manufacture) (2009-2026)	245
Fig 5.23:	Average Rates of Failure, by Primary Cause, and Phase of Manufacturing ("Clinical" Scale) (2009-2026)	247

Fig 5.24:	Global Quality Supply Management (2011-2013, 2022-2023).....	251
Fig 5.25:	Global Quality Supply Management, Biomanufacturers vs. CMOs, 2023	252
Fig 5.26:	Global Quality Supply Management (U.S. vs. W. Europe), 2023.....	253
Fig 5.27:	Addressing Supply Chain Security (2023-2026)	255
Fig 6.1:	Industry Average Planned Production Increase: Five Year Estimates (2031).....	261
Fig 6.2:	Planned Future Capacity Expansion: Five Year Estimates (2009–2031)	263
Fig 6.3:	Percentage of Respondents Projecting Production Increases over 100%: Five Year Trend (2031)	265
Fig 6.4:	Average Planned Future Capacity Expansion: Five-Year Estimates, Biomanufacturers vs. CMOs, by 2031	267
Fig 6.5:	Average Planned Future Capacity Expansion: Five-Year Estimates, U.S. vs. Western Europe, by 2031	270
Fig 7.1:	Current Percent Production Outsourced; by System, 2026	280
Fig 7.2:	Biopharmaceutical Manufacturing Facilities Outsourcing NO Production (2006-2026)	282
Fig 7.3:	Current Percent Respondents Outsourcing up to 50% of Production, by System, 2009-2026	283
Fig 7.4:	Biomanufacturers' Outsourcing, Five Year Projections, by System (2031).....	286
Fig 7.5:	Five-year Projections: % Biotherapeutic Manufacturers Planning to Outsource at Least Some Production; Projections made 2007-2026.....	288
Fig 7.6:	Biomanufacturers Outsourcing Some Activity Today, 2026.....	291
Fig 7.7A:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2026)	293
Fig 7.7B:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2026)	294
Fig 7.8:	Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years (2026).....	297
Fig 7.9A:	Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, Trends (2010-2026)	299
Fig 7.9B:	Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, Trends (2010-2026)	300
Fig 7.10:	Estimated Average Percentage of Activity Outsourced, by Facilities Today, 2026...302	
Fig 7.11A:	Estimated Average Percent of Activity Outsourced by Facilities (2010-2026)	304
Fig 7.11B:	Estimated Average Percent of Activity Outsourced by Facilities (2010-2026)	305
Fig 7.12:	Change in Spending on Outsourcing for R&D or Manufacturing, Next 12 months (2012-2026)	307
Fig 7.13:	Average Change in Outsourcing Spending by Facilities, (2013-2026), with 2-year moving average	308
Fig 7.14:	Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations, 2026.....	310
Fig 7.15:	'Very Important' Issues for Considering Outsourcing to CMOs, Percentage Point Shifts Over Time (2006-2018, 2025-2026)	312
Fig 7.16:	U.S. BioSecure Act INFLUENCE Choice of Commercial-scale Contract Manufacturers (CMOs) or Outsourcing Vendors, 2025.....	316
Fig 7.17:	Percent Indicating USA as Likely or Strong Likely Selection for INTERNATIONAL (non-US respondents) Outsourcing Over Next Five Years, 2009-2026 (targeting 2031)	317

Fig 7.18:	Country Selections for International Outsourcing/Capacity Expansion Over Next Five Years, 2031	319
Fig 7.19A:	Country Selections for “Possible” International Outsourcing/Capacity Expansion Over Next Five Years (2016-2026).....	321
Fig 7.19B:	Country Selections for “Possible” International Outsourcing/Capacity Expansion Over Next Five Years (2016-2026)	322
Fig 7.20A:	U.S. Respondents Considering International Country as “Possible” International Outsourcing Destination, over Next Five Years (2009-2026)	325
Fig 7.20B:	U.S. Respondents Considering International Country as “Possible” International Outsourcing Destination, over Next Five Years (2009-2026)	326
Fig 7.21:	U.S. Respondents Considering Country as “Strong likelihood” or “Likelihood” as Outsourced Capacity Destination, Next Five Years (2031)	328
Fig 7.22A:	Western European Respondents Considering Country as “Possible” Outsourcing Destination, Next Five Years, (2009-2026).....	331
Fig 7.22B:	Western European Respondents Considering Country as “Possible” Outsourcing Destination, Next Five Years, (2009-2026).....	332
Fig 7.23:	Western European Respondents Considering Country as ‘Strong likelihood’ or ‘Likelihood’ as Outsourced Capacity Destination, over Next Five Years (2031)	334
Fig 7.24:	Percent of Biomanufacturing Operations Offshored (International Outsourcing) to Lower-Cost Regions Within Five Years (2031)	337
Fig 7.25:	Percent of Biomanufacturers Performing at Least “Some” International Outsourcing/Offshoring to Lower-Cost Regions Over Next Five Years (2011-2026).....	339
Fig 7.26:	Estimated Average Percentage of Operations to be Done as International Outsourcing/ Offshoring to Lower-Cost Regions During Next Five Years (2011-2026)	341
Fig 8.1:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture, 2026	348
Fig 8.2A:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2026)	350
Fig 8.2B:	Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2026)	351
Fig 8.3:	Average Annual Growth Rate, Disposables (2006-2026)	354
Fig 8.4:	20-Year Percentage-Point Increase in First Usage of Disposables (2006-2026).....	356
Fig 8.5:	Usage of Disposables in Biomanufacturing by Stage of Manufacture (R&D–Commercial), 2026	358
Fig 8.6:	Usage of Disposables in Biopharmaceutical Manufacturing: Biomanufacturers vs. CMOs, 2026	360
Fig 8.7:	Reasons for Increasing Use of Disposable System Components, 2026	363
Fig 8.8:	Reasons for Increasing Use of Disposable System Components, 2006-2015, 2026	365
Fig 8.9:	Reasons for Restricting Use of Disposables, 2026.....	368
Fig 8.10:	Factors Restricting Use of Disposables (2006-2015, 2025-2026)	370

Fig 8.11:	Time Since Facility's Last Failure of Single-use Devices and Equipment, 2026.....	374
Fig 8.12:	Average Weeks Before Failure of Single-use Devices and Equipment (2023-2026)	376
Fig 8.13:	Need for Improved Single-Use Sensors, 2012-2017, 2019, 2026	378
Fig 8.14:	Single-Use Product Vendor Satisfaction Factors (2008-2026)	381
Fig 8.15:	Importance of Single-Use Product Attributes vs. Level of Vendor Satisfaction, 2026	383
Fig 8.16:	Percentage Point Gap between Importance of SUS Product Attributes and Level of Satisfaction (2013-2026)	386
Fig 8.17:	Estimated Percentage of Facilities' Unit Operations that Are "Single-Use" (2014-2026)	388
Fig 8.18:	Distribution of Responses, % Single-Use Devices in Biomanufacturing, 2026.....	390
Fig 9.1:	Impact of Downstream Processing on Overall Capacity (2008-2026)	400
Fig 9.2:	Impact of Downstream Processing on Overall Capacity; Biomanufacturers vs. CMOs, 2026	402
Fig 9.3:	Impact of Downstream Processing on Overall Capacity; U.S. vs. Western Europe, 2026.....	404
Fig 9.4:	Impact on Capacity of Depth, Chromatography and UF Purification Steps, 2026 ...	405
Fig 9.5:	Impact on Capacity of Purification Steps: Experiencing at 'Significant' or 'Severe' Constraints (2008-2026)	407
Fig 9.6:	Impact on Capacity of Purification Steps, U.S. vs. Western Europe, 2026.....	409
Fig 9.7:	Issues Regarding Protein A Usage (2022).....	410
Fig 9.8:	Issues Regarding Protein A Usage (2009-2017, 2020-2022)	411
Fig 9.9:	mAb Operations: Upstream Production Titer (Distribution of Responses (2014 -2016, 2018-2026)	414
Fig 9.10:	Bioreactor Output at which DOWNSTREAM Purification Train Becomes Bottlenecked (2014-2016, 2018-2026)	416
Fig 9.11:	New Downstream Processing Solutions, 2026	418
Fig 9.12A:	New Downstream Processing Solutions Comparison (2010-2026)	420
Fig 9.12B:	New Downstream Processing Solutions Comparison (2010-2026)	421
Fig 9.13:	New Downstream Processing Solutions: Biomanufacturers vs. CMOs, 2026	423
Fig 9.14:	New Downstream Processing Solutions: U.S. vs. Western Europe, 2026.....	425
Fig 9.15:	Improving Downstream Operations, (2011-2019, 2025-2026).....	428
Fig 9.16:	Most Important Fill-Finish Trends (2015-2017, 2025)	431
Fig 9.17:	Novel Fill-Finish Technology Implementation Plans within 24 Months (2015-2017, 2025)	433
Fig 9.18:	Average Downstream Processing (DSP) Yield	435
Fig 9.19:	Percent Point Change in DSP Yield - Past 2 Years vs Today	436
Fig 10.1:	New Hires in Biopharmaceutical Manufacturing, 2026	447
Fig 10.2:	Estimated % of Hiring in Biopharmaceutical Manufacturing, by Operational Area, (2008-2026).....	449
Fig 10.3:	New Hires in Biopharmaceutical Manufacturing in Five Years (2031)	450
Fig 10.4:	Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, 2026	452

Fig 10.5A: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2026)	454
Fig 10.5B: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2026)	455
Fig 10.6: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, U.S. vs. Western Europe, 2026.....	458
Fig 10.7: Skills or Hands-On Training Required in NEW HIRES in GMP Bioprocessing (2023-2026).....	460
Fig 11.1: Future of Continuous Bioprocessing and Process Intensification, 2026.....	470
Fig 11.2: Future of Continuous Bioprocessing and Process Intensification (2018-2025)	473
Fig 11.3: Concerns Over Perfusion Processes vs. Batch-fed Processes in Bioprocessing, 2025	476
Fig 11.4: Perfusion Operations Issues (2011 – 2014, 2016, 2020, 2023-2025).....	478
Fig 11.5: Facilities Evaluating CBP Technologies Over the Next 12 Months (Upstream) (2016-2025)	480
Fig 11.6: Facilities Evaluating CBP Technologies Over Next 12 months (Downstream) (2016-2025).....	482
Fig 11.7: Automation Technologies Implemented/to be Implemented in 2026.....	485
Fig 11.8: Automation Technologies to be Implemented; Comparing (2009 - 2013, 2022-2026)	487
Fig 11.9: Most Common Factors Inhibiting Greater AUTOMATION of your Facility's Bioprocessing Today, 2026	489
Fig 11.10: Bioprocessing Activities Using AI in Next 2 Years (2028)	492
Fig 11.11: Biggest Problems/Hurdles to Facility's Implementing Artificial Intelligence (AI) tools in Bioprocessing, 2026	494
Fig 11.12: Respondents Currently Using or Considering Artificial Intelligence (AI) Application/Approaches at Bioprocessing Facility: TODAY vs 2 YEARS:.....	496
Fig 11.13: Most Needed Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure (2019-2025)	500
Fig 11.14: Most Needed Gene Therapy Manufacturing Improvements, Systems, Platforms and Infrastructure (2019-2025)	503
Fig 11.15: Cell or Gene Therapy Plans for GMP and Commercial Manufacturing (2020-2025)	506
Fig 11.16: Cell Therapy Capacity Plans for In-House Bioprocessing Facilities Next Five Years (2030)	508
Fig 12.1: Area of Biopharmaceutical Involvement, Vendor, 2026	519
Fig 12.2: Area of Biopharmaceutical Involvement, Vendor (2010-2026)	520
Fig 12.3A: In Which Geographic Regions/Countries Does Your Company Currently Actively Sell (2008-2026)	522
Fig 12.3B: In Which Geographic Regions/Countries Does Your Company Currently Actively Sell (2008-2026).....	523
Fig 12.4: Vendor Respondents' Primary Job Function, 2026.....	524
Fig 12.5: Average Annual Vendor Sales Growth Rate (2007-2026).....	526

Fig 12.6:	Biopharmaceutical Supply Market Segment Sales Growth Distribution, 2026	527
Fig 12.7:	Average Annual Vendor Segment Sales Growth Rates, 2026	528
Fig 12.8:	Average Annual Vendor Sales Growth Rate, by Segment (2007-2026)	529
Fig 12.9:	Vendors' Approx. Annual Sales to Biopharmaceutical Segment % (2012-2026)	531
Fig 12.10:	Vendors' Average Budget Change, 2026	533
Fig 12.11:	Vendors' Average Budget Change, Summary (2009-2026)	535
Fig 12.12:	Vendors' Average Pricing Changes, Last Year (2026)	536
Fig 12.13:	Vendors' Average Pricing Changes, 2009-2025 Actual and 2026 Projected	538
Fig 12.14:	'Most Important' Factors to Measure The 'Quality' of Business Relationships with Suppliers, BIOMANUFACTURERS' PERSPECTIVE (2022-2026)	541
Fig 12.15:	'Most Important' Factors to Measure The 'Quality' of Business Relationships with Suppliers, SUPPLIERS vs. FACILITIES (2022-2026)	543
Fig 12.16:	Impact of COVID-19 Pandemic on Vendors, Percent Indicating an INCREASE in COVID-Related Factors (2021-2023)	546
Fig 12.17:	Permanent Changes caused by Pandemic on Your Business Operations (2024 vs 2025)	548
Fig 12.18:	Biopharma Business and Marketing Plans, 2026	551
Fig 12.19:	Biopharma Business and Marketing Plans (2010-2026)	553
Fig 12.20A:	Top New Technologies or New Product Development Areas (2011-2026)	555
Fig 12.20B:	Top New Technologies or New Product Development Areas (2011-2026)	556
Fig 12.20C:	Top New Technologies or New Product Development Areas (2011-2026)	557
Fig 12.21:	R&D Spending/Budgets for New Products/Services, 2026	560
Fig 12.22:	Approximate Average Annual R&D Spending/Budget for New Products/Services (2017-2026)	561
Fig 12.23:	Areas Where Training is Considered as Needed or Very Much Needed, All Vendor Respondents (2010-2026)	564
Fig 12.24:	Client Demands of Vendors, Service and Support (2012-2026)	566
Fig 12.25:	Vendors Views of Financial (Sales) Outlook for Next Year (2011-2026)	568
Fig 12.26:	Average CMOs Service Price Shifts over the "Past 12 Mo." (2010-2012, 2018-2026)	570
Fig 12.27:	CMOs Service Price Shifts Over Past 12 Months, Distribution, 2026	571

TABLES

Table 0.1:	Areas of Biopharmaceutical Manufacturing Operations (2018-2026)	9
Table 1.1:	Worldwide Revenue of Biopharmaceuticals (\$USD billions).....	27
Table 1.2:	Number of Biopharmaceutical Products in U.S. and European Markets, 2025-2026	31
Table 1.3:	Global Market for Top 50 Biopharma Products in (2024-2025, \$USD Million).....	33
Table 1.4:	Top 50 Biopharmaceutical Products vs Total Market Size (%) \$million.....	35
Table 1.5:	Bioprocess Related Industry Expenditures on Manufacture of Biotherapeutics (estimated \$USD, billions)	36
Table 1.6:	Summary of Worldwide Biopharmaceutical Revenue Growth by Product Class, 2007 and 2025	41
Table 2.1:	Biopharmaceuticals Approved by FDA, 2025	53
Table 2.2:	Biopharmaceuticals Approved by FDA in 2026 (Till May'2026)	54
Table 2.3:	Facility Takeovers Involving CDMOs.....	60
Table 2.4:	M&A Transactions Involving CDMOs	61
Table 3.1A:	Areas of Significant Projected Budget Percentage Increases for Biomanufacturing (2011-2026).....	100
Table 3.1B:	Areas of Significant Projected Budget Percentage Increases for Biomanufacturing (2011-2026).....	101
Table 4.1:	Regional Distribution of Total Worldwide Average Capacity*	190
Table 4.2:	Leading Biopharma Company Capacity Estimates, 2026.....	192
Table 4.3:	Bioprocessing CMOs, Their Number of Facilities Worldwide and Estimated Total Capacity*	195
Table 4.4:	Compound Annual Change in mAb Titers (2008-2026)	198
Table 5.1:	Severe or Significant Capacity Constraints, by Stage of Production (2009-2026)...	203
Table 5.2:	Severe and Significant Capacity Constraints Today, U.S. vs. W. Europe (2010-2026)	209
Table 5.3:	Average Rates of Failure, by Primary Cause, and Phase of Manufacture (2017-2026)	243
Table 6.1:	U.S. Biomanufacturers' Five-Year Projected Capacity Increases, by System (2008-2026)	268
Table 6.2:	Western European Biomanufacturers' Five-Year Projected Capacity Increases, by System (2008-2026).....	269
Table 7.1:	Percentage of U.S.-based Respondents Indicating Country as a 'Strong likelihood' or 'Likelihood' as Outsourcing Destination (2009-2026)	329
Table 7.2:	Percent of Western European-based Respondents Indicating International Countries as a 'Strong likelihood' or 'Likelihood' as Outsourcing Destination (2011-2026).....	335
Table 9.1:	Percent of Biomanufacturers vs. CMO Facilities Experiencing "Serious" or "Some" Capacity Problems due to Downstream Processing (2008-2026).....	401
Table 9.2:	Percent of U.S. vs. Western Europe Facilities Experiencing 'Serious' Capacity Problems due to Downstream Processing (2009-2026)	403
Table 9.3:	Percent U.S. vs. Western Europe Facilities Not Expecting to see Bottlenecks due to Downstream Processing (2008-2026)	403
Table 9.4:	Upstream Production Titer vs. Max Capacity (2018-2026)	412
Table 12.1:	Average Vendor Sales and Technical Training Days (2011-2013, 2019-2021)	562

METHODOLOGY

This report is the 23rd in our annual evaluations of the state of the biopharmaceutical manufacturing (bioprocessing) industry. The strength of this study's methodology remains in its breadth of coverage, which yields a composite view from the respondents closest to the industry, its 23-year longevity, industry familiarity and high response rates. These permit a consistent approach which delivers reliable data and analysis.

Note, "biopharmaceutical" here refers to the classic biotechnology-grounded definition: involving manufacture of pharmaceuticals using biotechnology/bioprocessing. The term does not refer to the entire pharmaceutical industry or just those parts considered innovative, with "biopharmaceutical" now simply commonly substituted where "pharmaceutical" or "drug" were formerly used.

This year, BioPlan Associates, Inc. surveyed 300 qualified and responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations in 21 countries plus 121 industry vendors and direct suppliers of materials, services, and equipment to this industry segment. Using a web-based survey tool, we obtained and evaluated information including regarding respondents' current capacity, production, novel technology adoption, human resources, quality, and outsourcing issues. We also assessed respondents' projected reasons for bottlenecks, and their perception of how these bottlenecks might be resolved.

This year, we continue to include new questions and chapters, including Artificial Intelligence Use and Applications, Continuous Bioprocessing and Process Intensification (Chapter 11.) Over the past few years, advances in technologies, platforms, expression systems, and single-use applications have increasingly made the bioprocessing segment an area of interest for such innovation.

We continue to partner with worldwide media and membership organizations to ensure a high response rate, and the most accurate overview of the worldwide biopharmaceutical industry and its bioprocessing sector. Our industry partners are cited in our acknowledgments section. In addition, to supporting this coverage, we also acknowledge our media partners, whose assistance enables us to reach the many high-quality respondents required for this quantitative survey and analysis.

Further information on methodology, breakouts on specific segments, and data from earlier surveys may be requested by contacting us at the address below.

Thank you for your participation and interest in this important research.

Eric S. Langer
President
BioPlan Associates, Inc.
One Research Court, Ste. 450
Rockville, MD 20850
+1 301-921-5979
elanger@bioplanassociates.com
www.bioplanassociates.com

CHAPTER 0: DEMOGRAPHICS

KEY TAKEAWAYS

This is the 23rd year that we are capturing the evolution of the biomanufacturing industry. In this report we provide an internationally recognized, data-rich analysis of the biomanufacturing industry's past and present and offer expert insights about its future.

- **Survey respondents held senior roles:** Survey respondents include bioprocess professionals whose roles extend into the most senior levels of strategic decision-making at global biopharmaceutical organizations.
- **Global professional opinions:** The 2026 edition of this report incorporates survey responses from professionals across 22 countries, reflecting a global perspective with insights spanning North America, Europe, Asia-Pacific, and other strategically important regions.
- **Respondents' involvement crosses all development phases of biomanufacturing** and offers a comprehensive coverage of expertise and opinions, from early-stage research through clinical trials and commercial production.
- **The facilities surveyed in this study make up a significant portion** of the overall global biomanufacturing industry.
- **Single-use bioreactor sizes increase:** A longitudinal review of the reviewed facilities shows an increase in average size of single-use bioreactors, as the industry continues to move toward larger, commercial-scale SUS capacities, including growth from 527 L SUS devices in 2018 to 880 L average size SUS bioreactors today.
- **Stainless steel systems are still actively used,** and at larger capacities than single-use bioreactors. Over the past 7 years, however, we have seen a plateau in the average size of stainless-steel bioreactors, at around 3600 L.

INTRODUCTION

This report presents a comprehensive analysis based on the insights of a global cohort of senior executives, technical leaders, and scientific experts engaged in biopharmaceutical development and manufacturing. Respondents span a wide range of organizational roles and company types, including both Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs), in addition to biotherapeutic developers operating across diverse therapeutic areas.

This is the 23rd year that we continue to publish this internationally recognized research initiative. Our work has been serving as a benchmark for the biomanufacturing sector. The 2026 edition draws on survey responses from professionals in 21 countries, capturing perspectives from

across North America, Europe, Asia-Pacific, and other key regions. This global reach ensures that the report reflects both the local nuances and shared global challenges that shape the biopharmaceutical industry today.

This report goes beyond general industry snapshots, we aim to include focused data segments. In Chapter 12 we include additional highlights from bioprocessing suppliers and technology vendors. Chapter 12 also offers additional insights into the supply-side dynamics influencing manufacturing strategy and innovation. As in prior years, participating organizations range in size, market focus, and development stage, but all respondents share direct involvement in bioprocessing and manufacturing operations ensuring a grounded, practical understanding of current trends.

The strength of this report lies in the diversity and depth of experience represented. Contributors include hands-on professionals actively managing and executing biopharmaceutical manufacturing operations in addition to decision makers and portfolio managers. Their collective input provides a real-time view of how the industry is evolving, where the most pressing challenges lie, and what strategic directions are gaining traction.

To support nuanced interpretation, responses are analyzed in aggregate and also by organization type, distinguishing between CMOs and innovator biotherapeutic manufacturers. This organizational segmentation allows for more targeted insight into how different stakeholders are navigating business drivers, risk exposure, capital investment decisions, and operational strategy.

This report aims to deliver a clear, data-driven view of the industry's current landscape and future outlook shaped by those at the forefront of biomanufacturing innovation and execution.

0-1 RESPONDENTS' AREA OF INVOLVEMENT

In the 2026 survey, the highest number of respondents reported direct involvement in 'large-scale cell culture production for therapeutic' use (17.2%) and in 'process development for biopharmaceutical manufacturing' (17.0%). These two areas have consistently represented the largest share of respondent roles throughout our longitudinal study, due to their central importance within the biomanufacturing ecosystem.

This trend is reflective of the broader industry landscape, where upstream production and process development remain foundational to biopharmaceutical success. 'Large-scale cell culture production for therapeutics' is the engine of commercial biologics manufacturing. Likewise, 'process development for biopharmaceutical manufacturing' plays a critical role in translating discovery into scalable, regulatory-compliant manufacturing, making it a focal point for innovation, investment, and staffing across organizations.

Following these organizational areas, in 2026, we report 8.3% of survey responders that belong primarily to 'scale-up (or clinical-scale) production for biopharmaceuticals primarily' and 7.4% to 'large-scale microbial fermentation for therapeutics'.

Similar to previous reports, a smaller percentage of survey responders belongs to 'other contract manufacturing (CMO) for pharmaceuticals' (2.1%) and 'fill/finish operations' (2.1%). These percentages are representative of the portion of biomanufacturing professionals in the facilities surveyed.

We note the remaining ~25% of survey respondents were vendors/suppliers and their responses are reported on Chapter 12 of this analysis.

For Ordering Information on the
Full Report

Contact BioPlan Associates, Inc.

+1 301-921-5979

www.bioplanassociates.com/23rd

Twenty-Third Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Another report in the BioPlan Associates, Inc.'s biopharmaceutical series:

- Top1000 Global Biomanufacturing Facilities – Global analysis and ranking of capacity, employment, and pipelines, www.top1000bio.com
- Top300Bio CDMO Facility Index and Biomanufacturers Subscription Database – Global analysis and ranking of capacity, employment and pipeline for CDMOs, <https://www.top300cdmo.com>
- Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities, 2020
- Top 60 Distributors of Bioprocessing Supplies in China: Opportunities for Global Biopharma Suppliers to Find and Manage Local Distributors in China, 2020
- Top 100 Biopharmaceutical Organizations in China, Online Database
- Advances in Biopharmaceutical Technology in China, 2nd Ed., Soc. Ind. Microbiology, Biotech
- Quick Guide to Clinical Trials, 2nd Ed., 2017
- Biosimilars Pipeline Database, <http://www.biosimilarspipeline.com/index.html>
- Biopharmaceutical Expression Systems and Genetic Engineering Technologies
- Advances in Biopharmaceutical Manufacturing and Scale-up Production, Amer. Soc. Micro.
- Biopharmaceutical Products in the U.S. and European Markets, 8th Ed.
- Advances in Biopharmaceutical Technology in India
- Top 60 Biopharmaceutical Organizations in India
- Quick Guide to Biotechnology in the Middle East
- Quick Guide to Biofuels

The 23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. The survey includes responses from 300 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations from 21 countries. The survey methodology includes input from an additional 121 direct suppliers of raw materials, services, and equipment to this industry. In addition to current capacity issues, this study covers downstream processing problems, new technologies, expression systems, quality initiatives, human resources and training needs of biopharmaceutical manufacturers, growth rates of suppliers to this industry, and many other areas.

Copyright © 2026 by BioPlan Associates, Inc.

April 2026

ISBN 978-1-934106-53-2

